We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

J&J Seeks To Block Generic Topamax

Law360 (October 13, 2006, 12:00 AM EDT) -- Johnson & Johnson has asked a New Jersey district judge to prevent the launch of copycat versions of its lucrative epilepsy drug Topamax.

Johnson & Johnson’s preliminary injunction request, filed Thursday, came a month after the U.S. Food and Drug Administration cleared the way for Mylan Laboratories Inc. to sell Topiramate tablets in three dosage strengths—25 mg, 100 mg and 200 mg.

Topamax, which is covered by patents set to expire in 2008, boasts combined annual sales of approximately $1.4 billion for Johnson & Johnson....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.